Unigene initiates oral PTH Phase 2 study in postmenopausal women with osteoporosis

[News]

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today the dosing of the first subject in a Phase 2 study with an experimental oral parathyroid hormone analog for the treatment of osteoporosis in postmenopausal women.

More... (http://www.news-medical.net/news/20110316/Unigene-initiates-oral-PTH-Phase-2-study-in-postmenopausal-women-with-osteoporosis.aspx)